针对癌症的 PP2A 靶点：联合治疗。
Targeting PP2A in cancer: Combination therapies.
机构信息
Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Division of Genetic Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
出版信息
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1.
Abstract
The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome including pathways involved in apoptosis, proliferation and DNA damage response and PP2A inactivation is a vital step in malignant transformation. Many groups have explored the therapeutic venue of combining PP2A reactivation with kinase inhibition to counteract the very changes in tumor suppressors and oncogenes that lead to cancer development. Conversely, inhibition of PP2A to complement chemotherapy and radiation-induced cancer cell death is also an area of active investigation. Here we review the studies that utilize PP2A targeted agents as combination therapy in cancer. A potential role for PP2A in tumor immunity is also highlighted.
摘要
丝氨酸/苏氨酸磷酸酶 PP2A 调节包括凋亡、增殖和 DNA 损伤反应途径在内的大量磷酸化组，PP2A 的失活是恶性转化的关键步骤。许多研究小组已经探讨了将 PP2A 再激活与激酶抑制相结合的治疗方法，以对抗导致癌症发展的肿瘤抑制因子和癌基因的变化。相反，抑制 PP2A 以补充化疗和放疗诱导的癌细胞死亡也是一个积极研究的领域。在这里，我们回顾了利用 PP2A 靶向药物作为癌症联合治疗的研究。还强调了 PP2A 在肿瘤免疫中的潜在作用。
相似文献
1
Targeting PP2A in cancer: Combination therapies.针对癌症的 PP2A 靶点：联合治疗。
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1.
2
Role of protein phosphatases in the cancer microenvironment.蛋白质磷酸酶在癌症微环境中的作用。
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):144-152. doi: 10.1016/j.bbamcr.2018.07.006. Epub 2018 Jul 17.
3
Therapeutic targeting of PP2A.靶向 PP2A 的治疗。
Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26.
4
Protein phosphatase 2A regulatory subunits and cancer.蛋白磷酸酶2A调节亚基与癌症
Biochim Biophys Acta. 2009 Jan;1795(1):1-15. doi: 10.1016/j.bbcan.2008.05.005. Epub 2008 Jun 3.
5
Physiologic functions of PP2A: Lessons from genetically modified mice.PP2A 的生理功能：基因修饰小鼠的启示。
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):31-50. doi: 10.1016/j.bbamcr.2018.07.010. Epub 2018 Jul 18.
6
All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.条条大路通PP2A：挖掘这种磷酸酶的治疗潜力。
FEBS J. 2016 Mar;283(6):1004-24. doi: 10.1111/febs.13573. Epub 2015 Nov 14.
7
Unraveling the complexity: A comprehensive analysis of the PP2A in cancer and its potential for novel targeted therapies.解析复杂性：癌症中 PP2A 的全面分析及其作为新型靶向治疗的潜力。
Neoplasma. 2023 Aug;70(4):485-499. doi: 10.4149/neo_2023_230806N411.
8
Functional importance of PP2A regulatory subunit loss in breast cancer.PP2A 调节亚基缺失在乳腺癌中的功能重要性。
Breast Cancer Res Treat. 2017 Nov;166(1):117-131. doi: 10.1007/s10549-017-4403-5. Epub 2017 Jul 25.
9
The interaction of SET and protein phosphatase 2A as target for cancer therapy.SET 与蛋白磷酸酶 2A 的相互作用作为癌症治疗的靶点。
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188578. doi: 10.1016/j.bbcan.2021.188578. Epub 2021 Jun 8.
10
Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.唑来膦酸联合丝氨酸/苏氨酸磷酸酶抑制剂通过降低 PP1 和 PP2A 的活性，增强激素难治性前列腺癌细胞系的细胞毒性和凋亡。
BJU Int. 2012 Dec;110(11 Pt C):E1147-54. doi: 10.1111/j.1464-410X.2012.11392.x. Epub 2012 Aug 9.
引用本文的文献
1
Resveratrol Impairs Insulin Signaling in Hepatic Cells via Activation of PKC and PTP1B Pathways.白藜芦醇通过激活蛋白激酶C和蛋白酪氨酸磷酸酶1B信号通路损害肝细胞中的胰岛素信号。
Int J Mol Sci. 2025 Aug 1;26(15):7434. doi: 10.3390/ijms26157434.
2
PTPA Governs Stress-Responsive Differentiation and Metabolic Homeostasis in .蛋白酪氨酸磷酸酶A在……中调控应激反应性分化和代谢稳态
Cells. 2025 Jun 3;14(11):835. doi: 10.3390/cells14110835.
3
Germline mutations in PPP2R1B in patients with a personal and family history of cancer.有个人和家族癌症病史患者中PPP2R1B的种系突变。
JCI Insight. 2025 Apr 3;10(9). doi: 10.1172/jci.insight.186288. eCollection 2025 May 8.
4
LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models.LB-100通过抑制多药耐药性胶质母细胞瘤和非小细胞肺癌细胞模型中P-糖蛋白的表达增强药物疗效。
Pharmaceutics. 2025 Feb 4;17(2):189. doi: 10.3390/pharmaceutics17020189.
5
Direct observation of small molecule activator binding to single PR65 protein.小分子激活剂与单个PR65蛋白结合的直接观察
NPJ Biosens. 2025;2(1):2. doi: 10.1038/s44328-024-00018-7. Epub 2025 Jan 16.
6
Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target.肿瘤微环境中的蛋白丝氨酸/苏氨酸磷酸酶：关键角色与有前景的治疗靶点
Theranostics. 2025 Jan 1;15(3):1164-1184. doi: 10.7150/thno.104529. eCollection 2025.
7
Protein Phosphatase 2A Promotes CD8 T Cell Effector Function through the Augmentation of CD28 Costimulation.蛋白磷酸酶2A通过增强CD28共刺激促进CD8 T细胞效应功能。
Research (Wash D C). 2025 Jan 2;8:0545. doi: 10.34133/research.0545. eCollection 2025.
8
Exploring the dynamic landscape of immunopeptidomics: Unravelling posttranslational modifications and navigating bioinformatics terrain.探索免疫肽组学的动态格局：揭示翻译后修饰并跨越生物信息学领域。
Mass Spectrom Rev. 2025 Jul-Aug;44(4):599-629. doi: 10.1002/mas.21905. Epub 2024 Aug 16.
9
A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.蛋白磷酸酶 2A 抑制与检查点免疫治疗联合：完美风暴。
Mol Oncol. 2024 Oct;18(10):2333-2337. doi: 10.1002/1878-0261.13687. Epub 2024 Jun 26.
10
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.癌基因信号的矛盾激活作为一种癌症治疗策略。
Cancer Discov. 2024 Jul 1;14(7):1276-1301. doi: 10.1158/2159-8290.CD-23-0216.
本文引用的文献
1
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.PP2A 抑制是 KRAS 突变肺癌细胞中一种可药物治疗的 MEK 抑制剂耐药机制。
Sci Transl Med. 2018 Jul 18;10(450). doi: 10.1126/scitranslmed.aaq1093.
2
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.当与 PD-1 阻断联合使用时，蛋白磷酸酶-2A 的药理学抑制可实现持久的免疫介导的抗肿瘤活性。
Nat Commun. 2018 May 29;9(1):2126. doi: 10.1038/s41467-018-04425-z.
3
Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.溴结构域蛋白BRD4抑制剂JQ1调节晚期肾细胞癌中的潜在预后分子。
Oncotarget. 2018 May 1;9(33):23003-23017. doi: 10.18632/oncotarget.25190.
4
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.聚腺苷二磷酸核糖聚合酶抑制剂在三阴性乳腺癌中的作用：揭示广泛的合成致死性。
Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.
5
The impact of phosphatases on proliferative and survival signaling in cancer.磷酸酶对癌症中增殖和存活信号的影响。
Cell Mol Life Sci. 2018 Aug;75(15):2695-2718. doi: 10.1007/s00018-018-2826-8. Epub 2018 May 3.
6
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia.PP2A 抑制使 BCR-ABL 人类白血病中的癌症干细胞对 ABL 酪氨酸激酶抑制剂敏感。
Sci Transl Med. 2018 Feb 7;10(427). doi: 10.1126/scitranslmed.aan8735.
7
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.蛋白磷酸酶 2A 抑制增强脊索瘤的放射敏感性并抑制肿瘤生长。
Neuro Oncol. 2018 May 18;20(6):799-809. doi: 10.1093/neuonc/nox241.
8
High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.CIP2A蛋白的高表达与I-III期非小细胞肺癌的肿瘤侵袭性相关，并与预后不良相关。
Onco Targets Ther. 2017 Dec 12;10:5907-5914. doi: 10.2147/OTT.S148250. eCollection 2017.
9
Specificity of research antibodies: "trust is good, validation is better".研究抗体的特异性：“信任固然好，验证则更佳”。
Hum Pathol. 2018 Feb;72:199-201. doi: 10.1016/j.humpath.2017.12.003. Epub 2017 Dec 13.
10
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.致癌性RAS信号通过稳定PD-L1 mRNA促进肿瘤免疫抗性。
Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub 2017 Dec 12.
Zotero 插件